VivoSeq
Oncology

Pituitary Tumor

16

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Pituitary Tumor is an emerging landscape with 16 programs across 7 companies. The most active players are Bristol-Myers Squibb, Novartis, GSK. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

13/100

Completion Rate

56/100

Attrition Rate

31/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2GSK logo

GSK

2 programs

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3R

RECORDATI GROUP

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

72%

Small molecule

13 of 18 classified programs — the dominant modality here.

28%ALL OTHERSMonoclonal antibody211%Peptide211%Radiopharmaceutical16%

Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Terminated3 · 23%
Unknown status2 · 15%
Active, not recruiting1 · 8%
Enrolling by invitation1 · 8%
Withdrawn1 · 8%

Clinical Trials

Trial Activity

13 trials

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04042753·9 enrolled
Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors
Enrolling by invitation·PPeking Union Medical College Hospital·Phase 1·NCT07254104·30 enrolled
Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor
Completed·YYonsei University·N/A·NCT02813044·82 enrolled
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Completed·EEndocyte·Phase 2·NCT01689727·40 enrolled
Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Completed·—·Phase 3·NCT00889525
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Completed·—·Phase 2·NCT00939523·9 enrolled
Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors
Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 4·NCT02351700·62 enrolled
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)
Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00612066·2 enrolled
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Terminated·—·Phase 2·NCT02749227·4 enrolled
Rosiglitazone in Treating Patients With Pituitary Tumors
Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00616642·1 enrolled
Temozolomide in Treating Patients With Invasive Pituitary Tumors
Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT00601289
Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach
Unknown status·MMahidol University·Phase 4·NCT03132259·124 enrolled
Infraorbital Nerve Block for Endoscopic Transsphenoidal Approach to Remove Pituitary Tumor
Unknown status·—·Phase 4·NCT04785222·63 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)